SCHEMBL477129

SCHEMBL477129

CNc1cc(-c2c(C)nc3ccc(N4CC5=CN(Cc6ccccc6)CC5C4)nn23)ccn1

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 4/20 0.39
DPP4 P27487 2/20 0.35
RIPK3 Q9Y572 2/20 0.33
PDE2A O00408 1/20 0.31
SMPD3 Q9NY59 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16495695 0.89 CSNK1E (0.38) CSNK1EDPP4RIPK3
SCHEMBL16496413 0.88 CSNK1E (0.37) CSNK1EDPP4RIPK3
SCHEMBL477024 0.82 HRH3 (0.46) CSNK1EDPP4RIPK3PDE2A
SCHEMBL477166 0.74 CSNK1E (0.50) CSNK1ERIPK3
SCHEMBL477167 0.74 CSNK1E (0.50) CSNK1ERIPK3
SCHEMBL477028 0.73 CSNK1E (0.52) CSNK1EDPP4RIPK3
SCHEMBL477156 0.73 CSNK1E (0.55) CSNK1E
SCHEMBL477157 0.73 CSNK1E (0.55) CSNK1E
SCHEMBL477063 0.70 HRH3 (0.52) CSNK1EDPP4RIPK3
SCHEMBL477022 0.69 HRH3 (0.48) CSNK1EDPP4RIPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331546-B1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2012-02-01 EP disclosed
EP-2331546-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF Sanofi-aventis (FR) 2011-06-15 EP disclosed
WO-2010018327-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-02-18 WO disclosed